Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824885 | 0.87 | KDR (0.36) | EGFRCYP1A2GAASMN1; SMN2NR3C2 | |
| SCHEMBL1386144 | 0.87 | NR3C2 (0.34) | EGFRCYP1A2GAASMN1; SMN2NR3C2 | |
| SCHEMBL1386555 | 0.82 | MEN1 (0.39) | EGFRCYP1A2MAPTKDRFLT1 | |
| SCHEMBL1929579 | 0.81 | KDR (0.52) | EGFRPTK6KDRPDGFRBKIT | |
| SCHEMBL1386333 | 0.81 | MAPT (0.36) | EGFRCYP1A2GAASMN1; SMN2MAPT | |
| SCHEMBL1383073 | 0.80 | CCNK (0.35) | EGFRCYP1A2GAASMN1; SMN2NR3C2 | |
| SCHEMBL1383615 | 0.79 | KDR (0.48) | EGFRPTK6MAPTKDRFLT1 | |
| SCHEMBL13955593 | 0.79 | FLT1 (0.43) | EGFRSMN1; SMN2PTK6MAPTKDR | |
| SCHEMBL1383596 | 0.75 | KDR (0.38) | EGFRMAPTKDRFLT1TNF | |
| SCHEMBL4832143 | 0.74 | MEN1 (0.36) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4837864-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| US-7323474-B2 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | claimed |
| EP-1254138-B1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2005-05-11 | — | — | EP | claimed |
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | BOLD GUIDO | 2004-10-21 | — | — | US | claimed |
| US-6706731-B2 | WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2004-03-16 | — | — | US | claimed |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | claimed |
| EP-1254138-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | Novartis AG (CH) | 2002-11-06 | — | — | EP | claimed |
| WO-2001058899-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | FLT1, FLT4, KDR | EGFR 15/4885CYP1A2 269/4885GAA 1930/4885 |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | FLT1, FLT4, KDR | EGFR 12/4885CYP1A2 374/4885GAA 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.